Mazdutide：Dual-Action Breakthrough for Obesity & Type 2 Diabetes Treatment
Hits: 371 Time: 2025.11.14
Mazdutide (also known as IBI362 or LY3305677) is a revolutionary dual GLP-1 and glucagon receptor agonist developed by Eli Lilly and Innovent Biologics, transforming metabolic disorder treatment. Approved in China for type 2 diabetes (T2D) and obesity/overweight management (BMI ≥27 or ≥24 with metabolic comorbidities), it delivers unmatched efficacy through a unique mechanism.
By activating both GLP-1 and glucagon receptors, Mazdutide targets energy balance holistically: it suppresses appetite via the hypothalamus, delays gastric emptying, and boosts fat breakdown/thermogenesis to increase energy expenditure . Clinical data confirms exceptional results: at 16mg, patients achieved 20-21% weight loss in 20 weeks (vs. 0.1% with placebo), with 66-75% losing ≥15% body weight . For T2D, it reduces HbA1c by 1.41-1.67% and improves insulin sensitivity .
Beyond weight and glucose control, Mazdutide offers multi-metabolic benefits: lowering LDL cholesterol (12.4%), triglycerides (18.2%), and liver fat content, while reducing blood pressure . Its long half-life (144 hours) enables once-weekly subcutaneous injection, enhancing patient adherence . Dose escalation (0.5mg →1.0mg →2.0mg) minimizes gastrointestinal side effects, which are mild-to-moderate and transient .
Currently in Phase 3 trials for obstructive sleep apnea and non-alcoholic fatty liver disease , Mazdutide represents a new standard in metabolic care. Its dual-action design, proven safety profile, and convenient dosing make it a preferred choice for patients and healthcare providers worldwide.
Wan Chai District, Hong Kong, China
